NARA Discovery
Article Details
← Back to Search Results
Journal Article

Changes in distinct brain systems identified with fMRI during smoking cessation treatment with varenicline: a review

Vassilis N. Panagopoulos; Alexis Bailey; George K. Kostopoulos; Andreas A. Ioannides
Psychopharmacology · Vol. 241, Issue 4 · pp. 653-685 · 2024

Abstract

Background Varenicline is considered one of the most effective treatment options for smoking cessation. Nonetheless, it is only modestly effective. A deeper comprehension of the effects of varenicline by means of the in-depth review of relevant fMRI studies may assist in paving the development of more targeted and effective treatments. Methodology A search of PubMed and Google Scholar databases was conducted with the keywords “functional magnetic resonance imaging” or “fMRI”, and “varenicline”. All peer-reviewed articles regarding the assessment of smokers with fMRI while undergoing treatment with varenicline and meeting the predefined criteria were included. Results Several studies utilizing different methodologies and targeting different aspects of brain function were identified. During nicotine withdrawal, decreased mesocorticolimbic activity and increased amygdala activity, as well as elevated amygdala-insula and insula-default-mode-network functional connectivity are alleviated by varenicline under specific testing conditions. However, other nicotine withdrawal-induced changes, including the decreased reward responsivity of the ventral striatum, the bilateral dorsal striatum and the anterior cingulate cortex are not influenced by varenicline suggesting a task-dependent divergence in neurocircuitry activation. Under satiety, varenicline treatment is associated with diminished cue-induced activation of the ventral striatum and medial orbitofrontal cortex concomitant with reduced cravings; during the resting state, varenicline induces activation of the lateral orbitofrontal cortex and suppression of the right amygdala. Conclusions The current review provides important clues with regard to the neurobiological mechanism of action of varenicline and highlights promising research opportunities regarding the development of more selective and effective treatments and predictive biomarkers for treatment efficacy.

Bibliographic Information

JournalPsychopharmacology
PublisherSpringer
Publication Date2024-04-01
Publication Year2024
Volume241
Issue4
Pages653-685
Document TypeJournal Article
Print ISSN0033-3158
eISSN1432-2072
DOI10.1007/s00213-024-06556-2

Access Information

NARA Access Coverage1959-01-01~Current
Journal Homepagehttps://www.springer.com/journal/213
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.